ERCC1、XPD、XPC单核苷酸多态性与局部晚期宫颈癌新辅助化疗敏感性的相关性

摘要
图/表
参考文献
相关文章 (3)

全文: PDF (1715 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：探讨DNA修复切除修复交叉互补基因1（ERCC1）、人类着色性干皮病D组基因（XPD）、人类着色性干皮病C组基因（XPC）基因多态性与局部晚期宫颈癌（LACC）铂类为基础的新辅助化疗（NACT）敏感性的关系。方法：经病理学确诊的LACC患者114例，所有病例化疗前抽取静脉血并提取DNA，采用聚合酶链式反应-限制性片段长度多态性分析（PCR-RFLP）技术检测单核苷酸多态性（SNPs），比较不同基因型与NACT疗效的关系。结果：携带ERCC1 Asn118Asn C/T基因型的化疗敏感率高于C/C基因型，差异有统计学意义（P＜0.05），携带C/T基因型化疗敏感性比C/C基因型增加4.48倍（OR=4.480；95%CI=1.436～13.976）。携带XPD Lys751Gln A/A基因型化疗敏感性高于A/C基因型，但差异无统计学意义（P＞0.05）。XPC Lys939Gln基因型与化疗敏感性差异无统计学意义（P＞0.05）。结论：ERCC1 Asn118Asn多态性可以预测以铂类为基础的LACC患者化疗疗效。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	祁丽芳
	吕杰强
	朱雪琼
	夏露
	黄秋穗
	屈王蕾
	陈文兵

关键词 ：局部晚期宫颈癌, 新辅助化疗, 单核苷酸多态性

Abstract：Objective: To investigate whether single-nucleotide polymorphisms of ERCC1, XPD, XPC affected response in locally advanced cervical cancer (LACC) receiving platinum-based neoadjuvant chemotherapy (NACT). Methods: A total of 114 patients who were pathologically diagnosed as cervical carcer treated with platinum-based neoadjuvant chemotherapy were examined for genotyping of ERCC1, XPD and XPC in peripheral blood lymphocytes with the method of polymerase chain reaction-restriction fragment length polymorphism (PCR-RPLF), and than the correlation between different genotypes with NACT curative effect was analized. Results: Variant genotypes of ERCC1 Asn118Asn were significantly associated with /C genetype LACC chemosensitivity (P<0.05). To compare ERCC1 Asn118Asn C/T genetype with ERCC1 Asn118Asn C/C genetype, chemosensitivity increased 4.48 times (odds ratio 4.48; 95%CI: 1.436-13.976; P<0.05). While no significant difference was found between chemotherapy response and SNPs of XPD condon 751 and XPC condon 939 (P>0.05). Conclusion: Our study provides evidence for the predictive role of ERCC1 Asn118Asn on chemotherapy response in LACC patients treated with.

Key words： locally advanced cervical cancer neoadjuvant chemotherapy polymorphism

收稿日期: 2016-01-04

基金资助:温州市科技局对外合作项目（H20080032）；正大青春宝肿瘤科研专项（2012ZYC-A34）。

通讯作者: 陈文兵，副教授，硕士生导师，主任医师，Email：fccwbqlf@sina.com。

作者简介: 祁丽芳（1985-），女，浙江温州人，住院医师，硕士。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2016/V46/I10/724

[1] ROTMAN M, SEDLIS A, PIEDMONTE M R, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study[J].Int J Radiat Oncol, 2006, 65(1): 169-176.
[2] DELGADO G, BUNDY B, ZAINO R, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 1990, 38(3): 352-357.
[3] Al-MANSOUR Z, VERSCHRAEGEN C. Locally advanced cervical cancer: what is the standard of care[J]. Curr Opin Oncol, 2010, 22(5): 503-512.
[4] 魏嘉, 刘宝瑞, 王亚平, 等. DNA修复基因单核苷酸多态性与铂类药物抵抗研究进展[J]. 中华肿瘤杂志, 2006, 28(3): 161-163.
[5] ROSELL R, LORD R V, TARON M, et al. DNA repair and cisplatin resistance in non-small-cell lung cancer[J]. Lung Cancer, 2002, 38(3): 217-227.
[6] FARNEBO L, JEDLINSHI A, ANSELL A, et al. Proteins and single nucleotide polymorphisms involved in apoptosis,growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines[J]. Int J Mol Med, 2009, 24(4): 549-556.
[7] TAKEKIDA S, FUJIWARA K, NAGAO S, et al. Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer[J]. Int J Gynecol Cancer, 2010, 20(9): 1563-1568.
[8] 董霞, 王刚. 局部晚期宫颈癌新辅助化疗影响因素研究进展[J]. 中华临床医师杂志(电子版), 2012, 6(15): 153-155.
[9] ROSE M C, KOSTYANOVSKAYA E, HUANG R S. Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer[J]. Genomics Proteomics Bioinformatics, 2014, 12(5): 198-209.
[10] World Health Organization. WHO handbook for reporting results of cancer treatment[M]. Geneva: WHO Offset publication, 1979: 16-21.
[11] REED E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy[J]. Cancer Treat Rev, 1998, 24(5): 331-344.
[12] KANG S, JU W, KIM J W, et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer[J]. Exp Mol Med, 2006, 38(3): 320-324.
[13] YU X, XIAO H, ZHAO B, et al. DNA repair gene ERCC1 C118T polymorphism predicts sensitivity of recurrent esophageal cancer to radiochemotherapy in a Chinese population [J]. Thorac Cancer, 2015, 6(6): 741-748.
[14] 张胜利. ERCC1和XPD基因SNPs与晚期NSCLC含铂类药物化疗敏感性的关系[D]. 苏州: 苏州大学, 2011.
[15] REN S, ZHOU S, WU F, et al. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patents treated with platinum-based chemotherapy [J]. Lung Cancer, 2012, 75 (1): 102-109.
[16] CHEN D Q, YAO X, ZHAO H Y, et al. DNA repair gene ERCC1 and XPD polymorphisms predict glioma susceptibility and prognosis[J]. Asian Pac J Cancer Prev, 2012, 13(6): 2791-2794.
[17] TISEO M, BORDI P, BORTESI B, et al. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin[J]. Br J Cancer, 2013, 108(8): 1695-1703.
[18] WU W, LI H, WANG H, et al. Effect of Polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients[J]. Plos One, 2012, 7(3): e33200.
[19] QIU M, YANG X, HU J, et al. Predictive value of XPD polymorphisms on platinum-based chemotherapy in nonsmall cell lung cancer: A systematic review and metaanalysis[J]. Plos One, 2013, 8(8): e72251.
[20] LI C, JIANG Z, LIU X. XPD Lys(751) Gln and Asp(312) Asn polymorphisms and bladder cancer risk:a meta-analysis[J]. Mol Biol Rep, 2010, 37(1): 301-309.
[21] BRADBURY P A, KULKE M H, HEIST R S, et al. Cisplat in pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes[J]. Pharmacogenet Genomics, 2009, 19(8): 613-625.
[22] 王连云, 吕杰强, 朱雪琼, 等. XRCC1和XPD多态性基因型与上皮性卵巢癌铂类药物敏感性的关系[J]. 温州医学院学报, 2013, 43(4): 227-227.
[23] VAN HOFFEN A, BALAJEE A S, VAN ZEELAND A A, et al. Nucleotide excision repair and its interplay with transcription[J]. Toxicology, 2003, 193(1-2): 79-90.
[24] OTT K, RACHAKONDA P S, PANZRAM B, et al. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2011, 18(9): 2688-2698.
[25] ZHU X L, SUN X C, CHEN B A, et al. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer[J]. Chin Med J (Engl), 2010, 123(23): 3427-3432.
[26] SALDIVAR J S, LU K H, LIANG D, et al. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients[J]. Gynecol Oncol, 2007, 107(1): 223-229.
[27] FLEMING N D, AGADJANIAN H, NASSANIAN H, et al. Xeroderma pigmentosum complementation group C single nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer[J]. Cancer, 2012, 118(3): 689-697.